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Abstract
Purpose Critically low skeletal muscle mass and strength, observed in 20% of people with chronic heart failure (CHF), 
reduces functional capacity, quality of life (QoL) and survival. Protein and essential amino acid (EAA) supplementation 
could be a viable treatment strategy to prevent declines in muscle strength and performance, and subsequently improve QoL 
and survival. This systematic review (PROSPERO: CRD42018103649) aimed to assess the effect of dietary protein and/or 
EAA supplementation on muscle strength and performance in people with CHF.
Methods Searches of PubMed, MEDLINE and Embase identified studies that reported changes in strength or muscle per-
formance following protein and/or EAA supplementation in patients with CHF. Following PRISMA guidelines and using 
predefined inclusion/exclusion criteria relating to participants, intervention, control, outcome and study design, two reviewers 
independently screened titles, abstracts and full manuscripts for eligibility. Risk of bias was assessed using Cochrane Risk 
of Bias Tool (RCTs) or Mixed Methods Appraisal Tool (cohort studies). Data were extracted for analysis using predefined 
criteria.
Results Five randomised controlled trials (RCT) and one cohort study met our inclusion criteria. All RCTs had a high risk 
of bias. The methodological quality of the cohort study was moderate. Heterogeneity of extracted data prevented meta-
analyses, qualitative synthesis was therefore performed. Data from 167 patients with CHF suggest that protein and/or EAA 
supplementation does not improve strength, but may increase six-minute walk test distance, muscle mass and QoL.
Conclusions The limited quality of the studies makes firm conclusions difficult, however protein and/or EAA supplementa-
tion may improve important outcome measures related to sarcopenia. High-quality randomised controlled studies are needed.
Keywords Heart failure · Sarcopenia · Cachexia · Frailty · Muscles · Amino acids · Diet
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Introduction
Chronic heart failure (CHF) affects 11.8% of people over 
the age of 60 years [1] and is a leading cause of death and 
disability [2]. Structural and functional cardiac abnormali-
ties, leading to imbalances between metabolic supply and 
demand, are the defining physiological characteristics of 
CHF [3]. A key phenotype of CHF is reduced cardiac out-
put (Q ̇) and arterial compliance, which collectively inhibit 
haemodynamic perfusion of skeletal muscle during physi-
cal activity [3]. Such impaired cardiovascular function may 
contribute to exercise intolerance; however, CHF also causes 
profound adverse changes to skeletal muscle physiology, 
which plays a significant role in mediating physical disabil-
ity [3].
Changes in skeletal muscle physiology occur in CHF 
patients who have either reduced (HFrEF) or preserved 
(HFpEF) left ventricular ejection fraction (LVEF) [4–8]. 
These changes have been described in detail elsewhere [4, 9] 
and include a decrease in the number of type I muscle fibres, 
a decrease in the oxidative capacity and cross-sectional area 
of type II muscle fibres, a reduction in mitochondrial volume 
within muscle fibres, a reduction in enzymes required for 
aerobic metabolism and an increase in glycolytic enzymes. 
Reduced skeletal muscle aerobic enzyme activity, mitochon-
drial density and perfusion matching with oxidative muscle 
fibres contribute to poor aerobic fitness, faster depletion of 
phosphocreatine and an earlier reliance on glycolytic path-
ways during exercise [4]. Patients with CHF are also more 
likely to suffer from muscle atrophy and reduced strength, 
a condition termed sarcopenia [10–12]. In CHF, sarcopenia 
is associated with an increased risk of premature mortality 
[13], a reduction in six-minute walk test (6MWT) distance 
and physical function, low aerobic fitness, and poor health-
related quality of life (HRQoL) [11, 14]. Treatments that 
are capable of reversing or preventing the development of 
sarcopenia in patients who have CHF are therefore needed.
Insufficient dietary protein intake is a strong predictor of 
developing sarcopenia in patients with heart disease [15]. 
Regular dietary supplementation with protein or essential 
amino acids (EAA) has been shown to augment skeletal 
muscle strength and mass in healthy adults [16], and in 
patients with a long-term condition; defined by the authors 
as, “including coronary artery disease, chronic heart failure, 
type 2 diabetes mellitus, chronic obstructive pulmonary dis-
ease, osteoporosis, the metabolic syndrome and dementia” 
[17]. This is most likely due to the capacity of dietary protein 
and/or EAA supplementation to stimulate the mammalian 
target of rapamycin (mTOR) pathway and muscle anabolism 
[18–20]. Protein and/or EAA supplementation may therefore 
help to improve strength and muscle performance in patients 
with CHF, however this has not been widely investigated.
The primary aim of this systematic review was to assess 
the effects of dietary protein and/or EAA supplementation 
on skeletal muscle strength and performance in people with 
CHF. The secondary aims were to explore the effect of this 
intervention on body composition, HRQoL, aerobic fitness 
and safety. Intervention adherence and adverse events were 
also reported.
Methods
This review adhered to the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) 
guidelines. A PRISMA checklist is available from Online 
Resource 1 [21]. A priori aims, eligibility criteria and meth-
ods were registered with PROSPERO (CRD42018103649).
Study selection criteria
The Participants, Intervention, Control, Outcomes and Study 
Type (PICOS) criteria are outlined in Table 1. Randomised 
controlled trials (RCT) and cohort studies were included if 
the intervention involved protein or EAA supplementation 
Table 1  PICOS criteria for 
included studies PICOS Criteria
Participants Heart failure patients with preserved ejection fraction
Heart failure patients with reduced ejection fraction
Intervention Dietary protein supplementation for at least 4 weeks
Dietary essential amino acid supplementation for at least 4 weeks
Control Standard medical care (no change in diet)
Modification of a control patient’s diet resulting in a lower pro-
tein intake, compared to intervention patients
Outcomes Muscle strength
Muscle performance
Study type Randomised controlled trial
Cohort study
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for at least 4 weeks. Protein supplementation was defined as 
a request for the participant to consume protein and/or EAA 
in addition to their habitual dietary intake. We conserva-
tively chose to include studies that had a supplementation 
period of at least 4 weeks because a recent systematic review 
that investigated protein supplementation in patients with a 
long-term condition, suggested that interventions as short as 
6 weeks may improve muscle strength and mass [17]. Fur-
ther inclusion criteria were: studies that recruited (1) male 
or female patients, (2) patients who were > 18 years, and (3) 
patients with a diagnosis of HFrEF or HFpEF. Studies were 
also required to have a primary outcome of skeletal muscle 
strength or performance. Examples of performance outcome 
measures included walking tests, the short physical perfor-
mance battery (SPPB) or gait speed, because these have been 
recommended in international sarcopenia guidelines [10]. 
Acceptable comparator groups included patients that were 
assigned to standard care (no change to diet) or the modifica-
tion of a patient’s diet that resulted in a lower protein intake 
in comparison with the intervention group.
Studies were excluded if: (1) research was conducted in 
animal models, (2) participants were < 18 years of age, (3) 
there was no dietary protein or EAA supplementation, (4) 
the supplementation period was less than 4 weeks or (5) 
data were from case reports. Systematic reviews were also 
excluded. Language of publication was not an exclusion 
criterion.
Search strategy
A search of PubMed, MEDLINE, and Embase, was con-
ducted from the dates of inception (1879, 1879 and 1947, 
respectively), to August 2018. Search terms, including medi-
cal subject headings (MeSH) were developed by SN and 
AOD. These were refined by an independent research librar-
ian who performed the literature search. The search strat-
egy combined keywords describing the primary condition 
[heart failure (MeSH) OR cardiac failure OR left ventricular 
failure] AND secondary condition [sarcopenia (MeSH) OR 
cachexia (MeSH) OR lean muscle OR muscle mass]. The 
strategy also included terms describing the ‘intervention’ 
[protein and amino acids (MeSH)]. There are numerous 
methods of assessing strength and muscle performance. To 
reduce the risk of excluding relevant articles, we did not 
restrict the outcome measures using specific search terms. 
A full search strategy is provided in Online Resource 2. The 
reference lists of manuscripts that met our inclusion criteria 
were also screened for articles that met our inclusion criteria 
(see below).
Study selection
After the search was completed, duplicate articles were 
removed. SN and AOD independently screened titles 
and abstracts in accordance with inclusion and exclu-
sion criteria. Full-text manuscripts of the abstracts that 
met our inclusion criteria were assessed against inclusion 
and exclusion criteria. Differences between the author’s 
lists of included studies were resolved through discussion 
between SN, AOD and ANA, at both stages of the review 
process. Data extraction was performed by SN using a pre-
established pro forma. AOD reviewed the extracted data 
against the original manuscripts.
Data extraction and analysis
The following data were extracted: muscle strength, 
muscle performance, body composition, aerobic fitness, 
HRQoL, age, sex and number of participants, LVEF, pri-
mary diagnosis (HFrEF or HFpEF), and description of 
the supplementation regime (type of supplement, dose, 
frequency and duration), attrition, adherence, and safety 
(adverse events, renal function). Transparent reporting of 
adverse events provides important context about the ben-
efit and risk profile of an intervention and should be an 
outcome reported in clinical trials [22]. Serious adverse 
events were defined as any event or reaction that resulted 
in death, life-threatening illness, hospital admission or 
prolongation of existing hospitalisation, persistent or 
significant disability or incapacity [23]. Adverse events 
were defined as an untoward medical event that occurred 
during activities required for the study [23], irrespective 
of whether they were thought to be related to the inter-
vention. Changes in renal function were also reported to 
explore the safety of protein and/or EAA supplementation 
in patients with CHF. Diets that are high in protein may 
be associated with a decline in renal function in patients 
with heart disease [24]. Where outcome measures were 
assessed at multiple time points, testing conducted closest 
to cessation of supplementation was included for analy-
sis. Attempts were made to contact corresponding authors 
when missing data were identified.
We planned to conduct meta-analysis on quantitative 
data extracted from included studies. Outcomes of inter-
est were extracted as inter-group mean difference, with 
standard deviation (±), or median with inter-quartile range 
(IQR), according to how they were reported in the original 
manuscript. Intra-group differences were reported, where 
inter-group differences were unavailable. Data dispersion 
reported as standard error of the mean (SEM) were con-
verted to standard deviations using the following equation:
SD= SEM ×
√
n
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where; SD is the standard deviation, SEM is the standard 
error of the mean and n is the number of participants in 
the group of interest. Improvements in an outcome variable 
were considered statistically significant if it achieved a sig-
nificance threshold outlined in an a priori sample size cal-
culation. Where sample size calculations were not provided, 
findings were considered significant if a P value < 0.05 was 
reported.
Risk of bias and quality appraisal
Randomised controlled trials (RCTs) meeting our study 
inclusion criteria were independently evaluated by SN and 
AOD for risk of bias, using the Cochrane Risk of Bias tool 
[25]. Bias attributed to patient selection, randomisation, 
blinding, attrition and data reporting was assessed. Studies 
with a high risk of bias in one or more domains were classi-
fied as high risk. Studies that had an unclear risk of bias in 
one or more domains, but were not considered to have any 
domains at high risk of bias, were classified as moderate 
risk. Any study meeting low-risk criteria for all domains 
was considered to be at low risk of bias. A methodological 
appraisal of cohort studies was undertaken by SN and ANA 
using the Mixed Methods Appraisal Tool (MMAT) [26]. 
Objective quality scoring is not recommended because it 
assigns unjustified weighting to different elements of trial 
design and reporting [25]. A subjective assessment was 
therefore undertaken (Online Resource 3).
Results
A PRISMA flow diagram is shown in Fig. 1. Searches iden-
tified n = 833, n = 469 and n = 732 articles from Embase, 
MEDLINE and Pubmed, respectively (total n = 2034). 
After the removal of duplicate articles (n = 1110), database 
searches identified 924 records. A further five articles were 
identified through hand searches (total n = 929). Fourteen 
full-text articles were retrieved after screening of titles and 
abstracts. Eight articles, including the five studies identi-
fied in the hand search, were excluded (Online Resource 
4) and six articles were retained for review [27–32]. Data 
reported within these manuscripts was heterogeneous and 
there was insufficient data to perform meta-analysis or quan-
titative synthesis due to the risk of generating misleading 
findings [33]. Data were therefore qualitatively synthesised. 
No authors responded to our request for further information.
Study characteristics
Study characteristics are reported in Table 2. One cohort 
study [32] and five RCTs [27–31] were identified. 
Fig. 1  PRISMA flow chart Records idenfied through database searching 
(n=2034)
Addional records idenfied through hand 
searching
(n=5)
Records aer duplicates removed
(n=929)
Records Screened
(n=929)
Studies included for qualitave synthesis
(n=6)
Studies included for quantave synthesis
(n=0)
Id
en
fi
ca
o
n
Records excluded (n=915) aer 
screening of tle and abstract
Sc
re
en
in
g
Full-text arcles assessed for eligibility
(n=14)
El
ig
ib
ili
ty
In
cl
ud
ed
Records excluded for qualitave review 
(n=8); 8 papers did not report ≥1 of our 
pre-established primary outcome 
measures. This included all five arcles 
idenfied in the hand search 
Records excluded for quantave 
review (n=6)
Duplicates removed (n=1110)
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One-hundred and three (n = 103) patients were recruited to 
intervention groups and 64 patients were recruited to control 
groups, providing a total population of 167 patients from six 
studies. One RCT did not report primary outcome data for 
their control group [28].
Patient inclusion criteria were different between studies. 
Reduced LVEF or New York Heart Failure (NYHA) clas-
sification II–IV was most frequently reported as the criteria 
to define heart failure [28, 30, 32]. Two studies specifically 
recruited patients with clinical signs of muscle depletion 
[27, 28]. Muscle depletion was defined as: > 7.5% oedema-
free weight loss in ≥ 6 months, excluding patients with signs 
of acute inflammatory processes, cancer, or severe chronic 
renal failure (serum creatinine > 250 μmol/L) [25], or age 
and sex adjusted arm circumferences in the lowest 10th 
percentile in accordance with data from Frischano and col-
leagues [35].
Risk of bias
All five RCTs had a high risk of bias (Table 3) [27–31]. 
Randomised controlled trials had between two and six 
domains that were considered to be at a high risk of bias. 
The methodological quality of the cohort study was consid-
ered moderate due to the length of the recruitment not being 
reported (Online Resource 3) [32]. Selective data reporting 
was common across all studies and numerical P-values were 
often unreported. Only one study reported a sample size 
calculation [30].
Duration of protein and essential amino acid 
supplementation
Intervention characteristics (Table 2) were heterogeneous. 
The duration of dietary supplementation of protein/EAA 
ranged from 6 weeks [30] to 6 months [31]. Three studies 
supplemented protein/EAA for 3 months [28, 29, 32] and 
one study supplemented protein/EAA for 2 months [27].
Daily protein and essential amino acid dose
Five out of six studies increased daily dietary protein and/
or EAA intake with supplementation. Among these five 
studies, two administered dietary protein; one used 1.5 g/
kg per day of whey protein powder [31] and one used a 
300 kcal of twice daily multi-macronutrient supplement 
containing 20 g of protein [28]. Three of the five studies 
administered an EAA supplement without further alter-
ation to the patient’s habitual macro, or micro nutrient 
intake. Two of these provided 4 g doses, twice daily [27, 
32] and one administered an 8 g dose, once daily [30].
Instead of increasing daily dietary protein and/or EAA 
intake by the same (relative or absolute) amount, one of 
the six studies adjusted daily dietary protein intake to meet 
20% of a patient’s daily estimated energy intake in both 
the intervention and the control groups [29]. Ten grams of 
protein was then removed from the daily diets of patients 
in the intervention group and replaced with 2 × 5 g of a 
combined EAA and non-EAA supplement [29]. Supple-
ment doses are shown in Table 2.
Combined interventional studies
One study combined protein supplementation with a 
home-based aerobic and resistance exercise training 
intervention [31]. Exercise was delivered via a DVD or 
pamphlet and aimed to improve ambulation, balance, lift-
ing and functional independence. Each 20-min exercise 
session was prescribed six times per week (three aerobic 
and three resistance exercise sessions on alternating days). 
This exercise training intervention was only prescribed to 
the supplemented group.
A second study combined EAA supplementation with a 
twice weekly (1 h per session) resistance exercise training 
programme [29]. Resistance exercise training consisted 
of a warmup that included mobility exercises (four sets 
of six different exercises) and skeletal muscle stretching 
(four sets of six different exercises). The conditioning 
phase also involved six different exercises. Each type of 
resistance exercise was conducted in four sets of 15–20 
repetitions. Barbell and exercise bands providing a resist-
ance between 500 and 1500 g were used. Both the control 
and the supplement intervention groups undertook this 
exercise protocol.
One study combined EAA (8 g/day) with 6.5 g/day of 
polyunsaturated fatty acid (fish oil) [30].
Table 3  Risk of bias table for included studies
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Aquilani et al. (2008) [27]
Rozentryt et al. (2010) [28]
Pineda-Juarez et al. (2015)
[29]
Wu et al. (2015) [30]
George et al. (2017) [31]
Lomabardi et al. (2014) [32] N/A N/A N/A N/A N/A N/A N/A
 European Journal of Nutrition
1 3
Control group characteristics
Control group designs varied between studies. Two control 
groups were provided with standard medical care (no pla-
cebo) [27, 31]. One received safflower oil and milk pow-
der of equivalent caloric intake [30]. Another received the 
same resistance exercise training programme provided to the 
intervention group, whilst having their dietary protein intake 
adjusted to 20% of their estimated daily energy intake [29]. 
Only one control group was provided with a placebo drink 
(12 kcal) of ‘similar taste and consistency’ [28].
Strength measurements
Three studies with a combined total of n = 46 interven-
tion patients and n = 41 control patients investigated 
changes in skeletal muscle strength [29–31] (Table 4). 
One of these studies included exercise prescription in the 
intervention group only [31], one study included exer-
cise prescription in the intervention and control groups 
[29] and one study did not prescribe exercise [30]. One 
study reported percentage changes in handgrip strength 
only [29], one reported changes in handgrip strength 
(numerical data unavailable) and isokinetic leg dynamom-
etry [30] and one reported both handgrip (kg) and quadri-
ceps (kg) strength, but did not provide information of how 
measurements were recorded [31]. No studies reported 
any statistically significant improvements in strength in 
patients assigned to the intervention, compared to patients 
in control groups.
Muscle performance measurements
Five studies assessed changes in muscle performance 
(6MWT or get up and go test, Table 5) [27, 28, 30–32], 
however, one of these studies did not quantitatively report 
intervention or control data [30]. Data on changes in mus-
cle performance were reported in four studies that included 
n = 74 intervention and n = 38 control patients. All four stud-
ies measured changes in 6MWT distance [27, 28, 31, 32], 
one of which also reported changes in timed get up and go 
[31]. One study did not report control data for the 6MWT 
(n = 6) [28] and one was a cohort study (n = 13) [32].
One study, where only the intervention group was pre-
scribed exercise, did not find an increase in 6MWT dis-
tance or timed get up and go among intervention patients 
(n = 3), when compared to control patients (n = 3) [31]. 
Three studies [27, 28, 32] including one cohort study [32], 
reported a significant improvement in 6MWT distance after 
the nutritional intervention (n = 57). Only one study con-
ducted inter-group statistical comparisons of changes in 
6MWT distance. 6MWT distance increased significantly 
Table 4  Changes in strength measurements (mean ± SD)
Mean change refers to changes in a measurement that occurred between the baseline assessment, and the assessment that immediately followed 
supplement cessation
I intervention group, C control group, BW body weight
a Inter-quartile range
Study Sample size (n =) Measurement of strength Mean change in strength (SD) Significant improvement
Pineda-Juarez et al. [29] I: 29
C: 26
Handgrip (dominant arm; kg) I: + 8.0 (− 6.8 to 15.3)a
C: + 11.4 (3.6 to 21.4)a
I: No—P > 0.05
C: No—P > 0.05
Inter-group: Not reported
Wu et al. [30] I: 14
C: 12
Isometric leg extension—peak torque/
BW (%)
I: 196.0 ± 37.4 to 206.0 ± 41.2
C: 177.0 ± 62.4 to 200.0 ± 69.3
I: No—P > 0.05
C: No—P > 0.05
Inter-group: No—P > 0.05
Isometric leg flexion—peak torque/
BW (%)
I: 90.0 ± 18.7 to 90.0 ± 18.7
C: 76.0 ± 20.8 to 90.0 ± 27.7
I: No–P > 0.05
C: No–P > 0.05
Inter-group: No–P > 0.05
Isokinetic leg extension–peak torque/
BW (%)
I: 153.0 ± 29.9 to 160.0 ± 33.7
C: 147.0 ± 58.9 to 173.0 ± 69.3
I: No–P > 0.05
C: No–P > 0.05
Inter-group: No–P > 0.05
Isokinetic leg flexion–peak torque/
BW (%)
I: 70.0 ± 18.7 to 77.0 ± 15.0
C: 61.0 ± 20.8 to 76.0 ± 31.2
I: No–P > 0.05
C: No–P > 0.05
Inter-group: No–P > 0.05
George et al. [31] I: 3
C: 3
Handgrip (right arm; kg) I: + 1.8 ± 1.6
C: + 2.4 ± 2.1
I: No—P > 0.05
C: No—P > 0.05
Inter-group: No—P > 0.05
Quadriceps Strength (kg) I: + 5.7 ± 1.0
C: + 10.2 ± 8.7
I: No—P > 0.05
C: No—P > 0.05
Inter-group: No—P > 0.05
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in intervention (331 ± 124 m to 405 ± 130 m), but not con-
trol patients (298 ± 142 m to 310 ± 155 m; P = 0.02) [27]. 
The RCT that did not report control data found an increase 
in 6MWT distance, from 366 ± 110  m to 410 ± 107  m 
(P = 0.020) [28]. In the cohort study, 6MWT distances 
increased from 439 ± 64 m to 474 ± 89 m (P = 0.006) [32]. 
The RCT that did not quantitatively report outcome data 
did not find significant between-group differences in 6MWT 
distance (P > 0.05) [30].
Body mass measurements
The results for body composition measurements are pre-
sented in Table 6. Three studies involving n = 73 intervention 
and n = 49 control patients reported changes in body mass 
[27–29]. One study, which prescribed exercise in the inter-
vention and control groups, did not find a significant increase 
in body mass among intervention patients, when compared 
to control patients (P > 0.05) [29]. One study reported an 
intra-group body mass increase from 55.9 ± 17.0  kg to 
58.2 ± 7.2 kg (P < 0.010) [27], however changes in body 
mass were not significantly greater than those found in the 
control group (P > 0.05). A third study found an increase in 
intra-group body mass, from 63.9 ± 9.4 kg to 65.5 ± 10.3 kg 
(P < 0.001) following the study intervention. However, no 
control data were reported and inter-group comparisons 
were not conducted [28].
Body mass index measurements
Four studies [27, 29, 30] including one cohort study 
[32] reported data for body mass index [BMI] (n = 77 
intervention and n = 55 control patients). Only one study 
reported a significant increase in BMI following supple-
mentation (22.5 ± 2.1 kg/m2 to 23.4 ± 1.9 kg/m2; P < 0.010) 
[27]. However, this change was not significantly different to 
changes reported in the control group.
Fat mass measurements
Two studies, including n = 37 intervention and n = 18 con-
trol patients, reported Dual X-ray Absorptiometry (DXA) 
derived changes in fat mass. One study reported no change 
in fat mass among intervention group patients, when com-
pared to control group patients (P > 0.05) [30]. The second 
study reported an increase in fat mass, from 15.6 ± 0.7 to 
16.6 ± 0.9 (P = 0.003) in the intervention group. No control 
data were reported and inter-group comparisons were not 
conducted [28].
Lean mass measurements
Two studies, including n = 37 intervention and n = 18 con-
trol patients reported DXA derived changes in lean body 
mass [30]. Wu and Colleagues [30] reported that lean body 
mass significantly increased when compared to controls 
(P = 0.04). Rozentryt and colleagues [28] reported that 
lean body mass increased among intervention patients 
(P = 0.019), but did not report control data.
One study (intervention arm n = 21; control arm n = 17) 
estimated lean body mass using tricep skinfold thickness 
measurements and arm muscle area  (cm2) [27]. Tricep skin-
fold thickness measurements did not change in either study 
groups (P value not reported). Arm muscle area increased in 
Table 5  Changes in muscle performance measurements (mean ± SD)
Study Sample size (n =) Measurement of muscle function Change in muscle function (SD) Significant improvement
Aquilani et al. [27] I: 21
C:17
6MWT (m) I: 331.0 ± 124.0 to 405.0 ± 130.0
C: 298.0 ± 142.0 to 310.0 ± 155.0
I: Yes—P < 0.001
C: No—P > 0.05
Inter-group: Yes—P = 0.02
Rozentryt et al. [28] I: 23
C:6
6MWT (m) I: 366.0 ± 110.0 to 410.0 ± 107.0
C: Not Reported
I: Yes—P = 0.020
C: No—P > 0.05
Inter-group: Not reported
Wu et al. [30] I: 14
C: 12
6MWT (m) I: Numerical values not reported
C: Numerical values not reported
I: No—P > 0.05
C: No—P > 0.05
Inter-group: No—P > 0.05
George et al. [31] I: 3
C: 3
6MWT (m) I: − 49.0 ± 42.0
C: − 43.0 ± 37.0
I: No—P > 0.05
C: No—P > 0.05
Inter-group: No—P > 0.05
Get Up and Go (seconds) I: + 1.8 ± 2.8
C: + 2.8 ± 4.3
I: No—P > 0.05
C: No—P > 0.05
Inter-group: No—P > 0.05
Lombardi et al. [32] I: 13
C: N/A
6MWT (m) I: 439.1 ± 64.3 to 474.2 ± 89.0
C: N/A
I: Yes—P = 0.006
C: N/A
Inter-group: N/A
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the intervention and control groups (P = 0.020). One study 
(intervention arm n = 29; control arm n = 26; exercise pre-
scribed to both groups) reported arm circumference as an 
estimate of lean body mass [29]. There was no improvement 
in arm circumference among intervention group patients, 
when compared to control group patients (P > 0.05).
Aerobic fitness measurements
Five studies including n = 100 intervention and n = 61 con-
trol patients assessed changes in aerobic fitness (Table 7) 
[27–30, 32]. One study did not report control data [28], 
one was a cohort study [32], and one prescribed exercise to 
Table 6  Changes in measurements of body composition (mean ± SD)
Study Sample size (n =) Measurement of body composition Change in body composition (SD) Significant improvement
Aquilani et al. [27] I: 21
C:17
Arm muscle area (Skin fold 
measurement-derived;  cm2)
I: 31.2 ± 9.9 to 34.9 ± 10.0
C: 34.2 ± 5.0 to 37.1 ± 4.0
I: Yes—P < 0.020
C: Yes—P < 0.020
Inter-group: P > 0.05
Tricep skinfold thickness (mm) I: 10.4 ± 4.4 to 10.3 ± 3.9
C: 11.9 ± 3.7 to 11.4 ± 3.7
I: No—P > 0.05
C: No—P > 0.05
Inter-group: No—P > 0.05
Body mass (kg) I: 55.9 ± 17.0 to 58.2 ± 7.2
C: 60.8 ± 7.0 to 61.2 ± 6.3
I: Yes—P < 0.010
C: No—P > 0.05
Inter-group: No—P > 0.05
BMI (kg/m2) I: 22.5 ± 2.1 to 23.4 ± 1.9
C: 23.2 ± 1.4 to 23.6 ± 1.5
I: Yes—P < 0.010
C: No—P > 0.05
Inter-group: No—P > 0.05
Rozentryt et al. [28] I: 23
C:6
Lean body mass (DXA; kg) I: 45.0 ± 12.5 to 45.5 ± 11.2
C: Not reported
I: Yes—P = 0.019
C: No—P > 0.05
Inter-group: Not reported
Fat mass (DXA; kg) I: 15.6 ± 8.9 to 16.6 ± 8.9
C: Not reported
I: Yes—P = 0.003
C: No—P > 0.05
Inter-group: Not reported
Body mass (DXA; kg) I: 63.9 ± 9.4 to 65.5 ± 10.3
C: Not reported
I: Yes—P = 0.003
C: No—P > 0.05
Inter-group: Not reported
Pineda-Juarez et al. [29] I: 29
C:26
Body mass (kg) I: − 0.6 (− 4.4 to 2.1)a
C: -0.5 (− 2.4 to 2.7)a
I: No—P > 0.05
C: No—P > 0.05
Inter-group: No—P > 0.05
BMI (kg/m2) I: − 0.4 (− 2.7 to 2.2)a
C: − 0.7 (− 2.1 to 2.3)a
I: No—P > 0.05
C: No—P > 0.05
Inter-group: No P > 0.05
Arm circumference (% change) I: − 2.0 (− 7.4 to 3.3)a
C: − 4.0 (− 7.6 to 0.2)a
I: No—P > 0.05
C: No—P > 0.05
Inter-group: No P > 0.05
Hip circumference (% change) I: − 3.1 (− 6.6 to − 1.1)
C: − 1.5 (− 3.7 to − 1.8)
I: No—P > 0.05
C: No—P > 0.05
Inter-group: No P > 0.05
Waist circumference (% change) I: − 0.7 (− 3.2 to − 3.3)
C: − 1.7 (− 3.7 to − 1.8)
I: No—P > 0.05
C: No—P > 0.05
Inter-group: No P > 0.05
Wu et al. [30] I: 14
C: 12
Lean body mass (DXA; kg) I: 54.4 ± 2.8 to 56.1 ± 2.5
C: 52.4 ± 11.1 to 53.8 ± 12.8
I: Yes—< 0.05
C: No—P > 0.05
Inter-group: Yes P = 0.040
Fat mass (DXA; kg) I: 27.0 ± 7.5 to 26.0 ± 7.5
C: 25.0 ± 6.9 to 26.0 ± 6.9
I: No—P > 0.05
C: No—P > 0.05
Inter-group: No P > 0.05
BMI (DXA; kg/m2) I: 30.0 ± 1.0 to 30.0 ± 1.0
C: 28.0 ± 2.0 to 29.0 ± 2.0
I: No - P > 0.05
C: No - P > 0.05
Inter-group: No P > 0.05
Lombardi et al. [32] I: 13
C: N/A
BMI (kg/m2) I: 25.7 ± 3.2 to 25.4 ± 2.8
C: N/A
I: No
C: N/A
Inter-group: N/A
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the intervention and control groups [29]. Three studies did 
not find any changes in either estimated (P > 0.05) [29], or 
directly determined peak oxygen uptake (VȮ2peak) following 
protein and/or EAA supplementation (P = 0.320 [28] and 
P = 0.260 [30]). One study reported a significant increase 
in V ̇O2peak (P < 0.050) and peak power (P < 0.010) output 
among intervention patients, when compared to control 
patients [27]. The cohort study reported significant improve-
ments in V ̇O2peak (P = 0.008) and the ventilatory anaerobic 
threshold (P = 0.002), but not peak power output (P = 0.380) 
or ventilatory efficiency (V ̇E/V ̇CO2 slope; P = 0.754) [32].
Health related quality of life measurements
Four studies reported changes in patient HRQoL [28, 
30–32]. Three, including one cohort study [32] assessed 
HRQoL using the Minnesota living with heart failure ques-
tionnaire (MLHFQ) [30, 32, 36]. Control data were not 
reported for either RCT. Two (of three) studies [28, 32] 
reported an improvement in MLHFQ scores. Rozentryt and 
colleagues [28] reported a change from 47 ± 23 to 37 ± 27 
(P < 0.001; control data not reported), whilst Wu and col-
leagues [30] reported an improvement from 36 ± 82 to 
24 ± 57 in the intervention, but not control group (P = 0.020; 
control data not reported). The same study also assessed 
changes in HRQoL using the Kansas City Cardiomyopa-
thy Questionnaire (KCCQ) [37]. They identified an over-
all improvement (73 ± 71 to 83 ± 45; P = 0.040), improve-
ments in social limitation (72 ± 90 to 86 ± 56; P = 0.006), 
and HRQoL (62 ± 101 to 75 ± 60; P = 0.004). Lombardi and 
colleagues [32] did not find an improvement in MLHFQ 
score (21 ± 14 to 25 ± 13; P = 0.321).
One study [31], which combined exercise with supple-
mentation in the intervention group only, reported changes 
in HRQoL using the Short Form Health Survey (SF-36) 
questionnaire [38]. Only scores for individual questionnaire 
items were reported. There were no significant changes in 
SF-36 scores for patients in the intervention (n = 3) or con-
trol groups (n = 3). Cumulative SF-36 scores and SEM val-
ues were not reported.
Safety
Four studies reported serious adverse event and adverse 
event data (Table 2) [27–30]. There were 21 serious adverse 
events. Eight of the serious adverse events were deaths 
[27–29] (4.8% of study population) [27, 28]. Four of the 
deaths were among intervention patients, and four among 
controls. One study involving exercise training for interven-
tion and control patients reported two deaths in each study 
Table 7  Changes in measurements of aerobic fitness (mean ± SD)
Study Sample size (n =) Measurement of aerobic fitness Change in aerobic fitness (SD) Significant improvement
Aquilani et al [27] I: 21
C:17
V̇O2peak (ml/kg/min) I: 13.5 ± 1.7 to 14.9 ± 1.9
C: 12.9 ± 2.7 to 13.0 ± 3.5
I: Yes—P < 0.050
C: No—P > 0.050
Inter-group: Yes—P < 0.050
Peak power output (w) I: 80.0 ± 28.0 to 95.0 ± 25.0
C: 85.0 ± 24.0 to 88.0 ± 22.0
I: Yes—P < 0.020
C: No—P > 0.050
Inter-group: Yes—P < 0.010
Rozentryt et al. [28] I: 23
C:6
V̇O2peak (ml/kg/min) I: 14.5 ± 2.9 to 14.9 ± 3.1
C: Not reported
I: No—P = 0.320
C: No—P > 0.050
Inter-group: Not reported
Pineda-Juarez et al. [29] I: 29
C:26
Estimated V̇O2peak (% change) I: + 16.6 (0.2 to 38.5)a
C: 50.1 (− 11.2 to 94.0)a
I: No—P > 0.05
C: No—P > 0.05
Inter-group: No—P > 0.05
Wu et al. [30] I: 14
C: 12
V̇O2peak (ml/kg/min) I: + 7.9 ± 17.6
C: + 0.1 ± 2.6%
I: No—No—P > 0.05
C: No—P > 0.05
Inter-group: No—P = 0.260
Lombardi et al. [32] I: 13
C: N/A
V̇O2peak (ml/kg/min) I:14.8 ± 3.9 to 16.8 ± 5.1
C: N/A
I: Yes—P = 0.008
C: N/A
Inter-group: N/A
VAT (ml/kg/min) I: 9.0 ± 3.8 to 12.4 ± 3.9
C:N/A
I: Yes—P = 0.002
C: N/A
Inter-group: N/A
V̇E/VCO2 slope I: 37.1 ± 6.9 to 37.4 ± 7.7
C: N/A
I: No - P = 0.754
C: N/A
Inter-group: N/A
Peak power output (w) I: 100.9 ± 32.4 to 104.8 ± 28.4 I: No—P = 0.380
C: N/A
Inter-group: N/A
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arm, however the cause of death was not reported (total 
deaths n = 4) [29].The absolute number of serious adverse 
events (n = 13) was higher among intervention patients com-
pared to controls (n = 8). However, due to a higher sample 
in the intervention compared to control group, the serious 
adverse event rate was proportionally similar among inter-
vention and control patients, with one serious adverse event 
for every eight patients recruited. There were a total of 28 
adverse events. Adverse events affected one in five patients 
assigned to intervention groups (total; n = 19), and one in 
seven patients assigned to control groups (total; n = 9). 
One study comprehensively reported adverse and serious 
adverse events [28]. The serious adverse events occurring 
in this study accounted for 52% of all serious adverse events 
(n = 14), and 72% of adverse events (n = 21) reported in 
our systematic review. Renal function was reported using 
estimated glomerular filtration rate (two studies) [29, 32], 
serum creatinine levels (four studies) [28–30, 32] and serum 
albumin levels (three studies) [28–30]. No changes in renal 
function were reported.
Study attrition
All six studies reported study attrition (Online Resource 5) 
[27–32]. Study attrition was similar among intervention and 
control arms. Attrition in the intervention arms ranged from 
0% to 50%, and attrition in the control arms ranged from 
0% to 40%.
Study adherence
Only one study reported supplementation adherence (Online 
Resource 5) [27]. Adherence was defined by the total num-
ber of empty supplement packets returned by the participant 
at the end of the intervention. Adherence was further evi-
denced by blood sample analyses, leucine (EAA) concentra-
tions within the intervention group were 279% higher than 
reported at baseline (P < 0.001). Based on this, the authors 
concluded that all participants adhered to the intervention.
Discussion
Overview
The primary aim of this systematic review was to assess the 
effects of dietary protein and/or EAA supplementation on 
skeletal muscle strength, and performance in patients with 
CHF. The number of studies (n = 6) and total patient popu-
lation (n = 167) were small, and the risk of bias was high 
in all RCTs. Methods of assessing our outcomes of inter-
est were also heterogeneous, and data were often incom-
pletely reported. For example, in most cases, only two 
studies reported the same outcome measure, and pooled 
sample sizes were small. In cases where three or more stud-
ies appeared to report the same outcome measure, complete 
intervention and control outcome data were only reported by 
two studies. Furthermore, data from the cohort study could 
not be pooled with data from the RCTs. The heterogene-
ous nature of these studies meant that meta-analysis was 
inappropriate [33]. Qualitative data synthesis suggested that 
dietary supplementation with protein and/or EAA may not 
improve strength in patients with CHF, [29–31] but may 
increase muscle performance (6MWT distance) [27, 28, 
32]. The secondary findings showed that protein/EAA sup-
plementation may improve lean body mass [28, 30], health-
related quality of life and appears to be safe. There is limited 
evidence for the intervention improving aerobic fitness.
Strength measurements
Recent changes to sarcopenia guidelines advocate primar-
ily identifying low muscle strength [10] instead of lean or 
fat-free body mass [39] for diagnosis. Developing an inter-
vention that can increase strength and avoid or defer the 
development of sarcopenia in patients with CHF is required. 
We identified three studies that measured changes in muscle 
strength, none of which reported a significant improvement 
following protein and/or EAA supplementation despite two 
of the studies employing a combined resistance exercise 
and protein/EAA intervention. Similar findings have pre-
viously been reported in non-frail elderly individuals [40], 
however evidence appears to support the beneficial role of 
protein and/or EAA supplementation in increasing strength 
in healthy adults [16] and undernourished people with a 
long-term condition [17].
A review of 49 studies by Morton and colleagues [16] 
reported a mean 1 repetition maximum (1RM) strength 
increase of 27.0 kg (95% CI 22.0–32.0 kg) following com-
bined resistance exercise training and protein supplemen-
tation in healthy adults. Dietary protein supplementation 
resulted in a further modest 1RM increase of 2.5 kg (95% 
CI 0.6–4.3 kg), indicating that protein supplementation plays 
a smaller role in improving strength, in comparison to resist-
ance exercise training. Similarly, a systematic review by 
Cheng and colleagues [17] found that dietary protein and/or 
amino acid supplementation elicited modest improvements 
in strength in people with a long-term condition (standard-
ised mean difference [SMD]: 0.27 kg; 95% CI 0.1–0.4 kg; 
P < 0.01) [17]. These findings appeared more pronounced 
in individuals who were undernourished. Interestingly, only 
one study identified by Cheng and colleagues [27] specifi-
cally recruited patients with CHF. Our findings confirm that 
there is a paucity of data in this population that has a high 
incidence of sarcopenia.
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Similar to our review, the review by Cheng and col-
leagues [17] extracted data from a study by Aquilani and 
colleagues [27]. Details of this intervention are reported in 
Table 2. Aquilani and colleagues measured aerobic fitness 
on a cycle ergometer. However, this was interpreted to be a 
measure of strength by Cheng and colleagues. Peak aerobic 
fitness is determined by oxygen transport to the muscle and 
muscle oxygen extraction [41] and may not reflect changes 
in muscular strength. Despite this important discrepancy, the 
findings of systematic reviews on protein and/or EAA sup-
plementation in older adults with [17] or without [40] long-
term conditions lend support to our observation that pro-
tein and/or EAA supplementation either does not improve 
or has a small effect on improving muscular strength [17, 
40]. This may be because muscular strength is dependent on 
neurological activation of the muscle, as well as increases in 
lean muscle mass [42]. Protein and/or EAA supplementa-
tion alone may not stimulate improvements in motor unit 
recruitment required for strength development. Mechanical 
stimuli, such as that provided by resistance exercise train-
ing, may be required to optimise the potential benefits that 
supplementation may provide.
We identified two studies that measured changes in 
strength following protein and/or EAA supplementation and 
exercise training. However, the study design limited the abil-
ity to adequately evaluate whether this combined approach is 
effective in improving strength. George et al. [31] assessed 
the feasibility of protein supplementation and exercise train-
ing in patients with CHF [31]. No significant improvements 
in strength were reported, however, the study was not pow-
ered to detect statistically significant changes in physiologi-
cal outcomes (n = 3 per study group) [31]. Pineda-Juarez and 
colleagues [29] also reported no improvement in strength 
among patients who were randomised to EAA supplemen-
tation or control groups. However, this study was limited 
by patients having an average energy intake of ~ 1423 kcal 
per day; a substantially lower dietary energy intake than is 
currently recommended for adult males and females (~ 2000 
to ~ 2500 kcal) [43]. Low dietary energy intake combined 
with increased energy expenditure with resistance exercise 
training may have exacerbated the catabolic nature of CHF 
[44]. Furthermore, Pineda-Juarez et al. [29] removed 10 g 
of protein from intervention patients’ diets, before providing 
the twice daily 5 g non-EAA and EAA mixture. Each 5 g 
supplement, however, only contained 3.75 g of non-EAA 
and EAA’s. Compared to baseline, patients in the interven-
tion group therefore consumed 2.5 fewer grams of protein 
per day than the control group, for the duration of the study 
[29]. Collectively, these factors may limit any expected 
improvements in strength, among patients assigned to the 
intervention group. Protein/EAA supplementation does not 
appear to improve strength of patients with CHF.
Body mass measurements
Three of five studies that measured body mass, reported an 
increase in at least one surrogate marker of lean muscle mass 
(arm muscle area, arm circumference and, BMI) [27, 28, 
30]. Two studies also reported an increase in DXA-derived 
measurements of lean body mass [28, 30], the reference 
standard for measuring body mass in sarcopenia [45]. Simi-
lar to data reported in healthy older people [16] and people 
living with a long-term condition [17], protein and/or EAA 
supplementation in patients with CHF led to an increase in 
lean body mass (DXA: 0.5–1.7 kg) [28, 30]. Protein/EAA 
supplementation appears to be beneficial in improving lean 
mass.
Despite increases in lean mass, Wu and colleagues [30] 
did not report any changes in fat mass, BMI or lipid pro-
files, suggesting that cardiometabolic health was maintained 
throughout the supplementation period. This study increased 
dietary energy intake by 90 kcal per day. However, Rozen-
tryt and colleagues [28] reported that a 300 kcal twice daily 
multi-macronutrient supplementation (20 g of protein, 72 g 
carbohydrate and 26 g of fat) led to an increase in total body 
mass and fat mass [28]. Given that 600 kcal/day constitutes 
approximately 35–45% of the daily energy expenditure of 
CHF patients [46], it is unsurprising that such an increase 
in dietary intake for 3 months led to increases in lean mass 
and fat mass.
Previous evidence suggests that mortality risk [47] and 
cardiac stress markers (NT-proBNP) [48] are lower in CHF 
patients who are overweight (BMI of up to 29 kg/m2). There-
fore, one might assume that the increases in body mass 
reported by Rozentryt and colleagues [25] are beneficial. 
However, high fat mass could be detrimental in CHF due to 
the observed higher level of inflammation (high-sensitivity 
C-reactive protein) and lower 6MWT distances [48]. High 
levels of inflammation may increase the risk of develop-
ing sarcopenia, and is associated with the progression of 
CHF [10, 49, 50]. Furthermore, greater six-minute walk test 
distances confer superior survival outcomes [51] and better 
HRQoL in patients with CHF [52]. Increasing body mass, 
without increasing fat mass may help to preserve 6MWT 
distance and consequently, HRQoL in people with CHF. 
Improved lean and total body masses without increased fat 
mass may be achieved with small increases in caloric intake 
(90 kcal) by predominantly supplementing with pro-anabolic 
EAA and non-EAAs [30].
Muscle performance
Three of the four studies that measured 6MWT distance 
reported a significant improvement among intervention 
patients, but not controls. The only study that did not report 
a significant improvement was a feasibility study with low 
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statistical power (n = 3 per group) [31]. Change in 6MWT 
distance exceeded the widely accepted minimally important 
improvement for people with CHF (43 m) [53] in two stud-
ies [27, 28]. These improvements are consistent with the 
effects of protein and/or EAA supplementation in people 
with a long-term condition [17] and similar to improve-
ments reported after exercise-based cardiac rehabilitation 
in patients with CHF (46 m; P < 0.001) [54].
It is noteworthy that the gold standard measurement of 
aerobic fitness, V ̇O2peak, increased in only two out of five 
studies [27, 32]. This may suggest that protein and/or EAA 
supplementation is more likely to improve sub-maximal 
muscle performance, rather than maximal aerobic fitness. 
Protein and EAA supplementation appears to improve mus-
cle performance assessed by walking distance.
Health‑related quality of life measurements
Changes in HRQoL were typically reported using the 
MLHFQ [28, 30] and the KCCQ [30]. The MLHFQ and 
KCCQ require patients to provide responses to questions 
relating to the impact that CHF has on their physical, 
emotional and socio-economic function. They are widely 
adopted in clinical trials involving patients with CHF and are 
likely to be sensitive to changes in frailty. However, to our 
knowledge, their sensitivity to changes in strength, muscle 
mass or performance has not been investigated. Therefore, 
it is possible that changes in HRQoL may not have been 
adequately captured. It is noteworthy that none of the stud-
ies in our systematic review used qualitative methods to 
explore changes in HRQoL. Qualitative research methods 
can provide important context to HRQoL data obtained from 
questionnaires and can help researchers to interpret quanti-
tative findings [55]. Qualitative research methods, such as 
patient interviews, could help to further our understanding 
of the impact the protein and/or EAA supplementation has 
on HRQoL. Based on the available evidence, protein and/
or EAA supplementation may lead to an improvement in 
HRQoL.
Attrition
In a RCT, high levels of patient attrition can increase the 
likelihood of a biased outcome and misleading findings [56]. 
Five out of six studies in our systematic review had an attri-
tion rate  < 20% [27–30, 32]. Attrition rates between 5% and 
20% are likely to lead to a modest risk of outcome bias in 
RCTs [57]. The observed low to modest risk of bias suggests 
that adequately powered RCTs, investigating protein and/or 
EAA supplementation, may be feasible.
Adherence
Recording adherence to nutritional supplementation in 
home-based interventions can be difficult. Only one study 
reported intervention adherence in our systematic review 
[27]. Adherence was estimated by counting the number 
of empty supplement packets those were returned to the 
research team and the increases in plasma EAA concentrac-
tions. It is promising that Aquilani and colleagues [27] found 
that 100% of patients adhered to their intervention. However, 
detailed information on adherence to protein and/or EAA 
supplementation in patients with CHF is required to deter-
mine whether patients are likely to adhere to protein and/or 
EAA supplementation in clinical practice.
Safety
Diets that are high in protein have been associated with a 
decline in renal function over a 41-month period, in patients 
with heart disease [24]. Therefore, the benefits of treating 
sarcopenia in patients with CHF using protein and/or EAA 
supplementation need to be evaluated against the risk of a 
decline in renal function. The data available in our system-
atic review suggest that interventions using protein and/or 
EAA supplementation that last up to 3 months [28, 30, 32] 
may not have a negative effect on renal function. However, 
this finding should be interpreted with caution, because 
adverse event reporting was often incomplete. Available 
adverse event data indicate that a proportionately similar 
number of adverse events were experienced by patients in 
intervention and control arms, and no significant safety con-
cerns have been identified in our systematic review. How-
ever, it is essential that future clinical trials in this field of 
research report adverse events in a transparent way [22].
Limitations
The paucity of studies that supplemented CHF patients 
with protein and/or EAA with the aim of improving mus-
cular strength or performance limited the strength of our 
findings. Furthermore, the risk of bias was high, outcome 
measures were heterogeneous and the quality of data report-
ing was varied, and often incomplete. This precluded meta-
analysis, and therefore estimation of the intervention effect 
size. The conclusions that can be drawn from our findings 
are therefore limited. Qualitative interpretation of the stud-
ies included in our review also indicated that a number of 
studies had design limitations. These may have influenced 
the outcomes of the studies and consequently our systematic 
review. One important design limitation was that only two 
studies prescribed and recorded exercise participation during 
the study. Exercise is a potent stimulator of muscle anab-
olism and strength, and patients with CHF are advised to 
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participate in structured exercise training, however, partici-
pation is highly variable. Not recording or controlling patient 
participation in structured exercise training may attenuate 
the overall effect signal for the protein/EAA intervention.
Future studies
It is clear from the small number of studies included in this 
review, and their recent publication dates, that this field of 
research is in its infancy. Future research should take into con-
sideration the high risk of bias and low quality of the study 
methods observed in the studies included in this review. To 
improve the quality of future research, transparent reporting 
of adverse events, reporting changes in renal function, adher-
ence to supplementation regimens, and qualitatively exploring 
patient experiences of participating in a protein and/or EAA 
supplementation regimen should be considered as priorities 
for future studies. Further qualitative research is needed to 
increase our understanding of how protein and/or EAA sup-
plementation may improve HRQoL in patients with CHF. 
This may be achieved, in part, by validation of the MLHFQ 
and KCCQ questionnaires against measurements of sarcope-
nia. Alternatively, validating sarcopenia specific question-
naires such as the recently developed SarQoL [58] in patients 
with CHF may provide additional information on changes 
in HRQoL following protein and/or EAA supplementation. 
Researchers should also consider whether using protein and/or 
EAA supplementation results in a significant increase in daily 
calorie intake, and what effect this may have on markers of car-
diometabolic health, inflammation and muscle performance. 
Finally, further research is needed to explore whether exercise 
training may augment any benefits associated with protein and/
or EAA supplementation for the treatment of sarcopenia in 
patients with CHF.
Conclusions
Protein and/or EAA supplementation appears to be safe, may 
increase lean body mass and 6MWT distance, but not strength 
in patients with CHF. Trials reporting changes in strength had 
substantial limitations and these findings should be interpreted 
with caution. Combining strength training with protein sup-
plementation optimises muscle strength and performance 
adaptations in healthy older participants. Research investi-
gating the benefits of protein and/or EAA supplementation 
combined with resistance exercise training in patients with 
CHF is needed.
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